---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065657"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:23:02.865626+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M

## Summary
- Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).
- Net loss $3.5M ($0.08/share) vs $3.8M loss last year; adj. EBITDA $(2.8)M.
- Record 700 patients added to pipeline (+42% YoY); backlog 249 units (-9%).
- Q2 2025 revenue guidance $9.0-9.5M; FY2025 reaffirmed at $50-53M.
- Medicare Part B patients 59% of Q1 revenue; 45% of revenue from in-quarter authorizations.

## SEC filing metadata
- accession: 0000950170-25-065657
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017025065657/0000950170-25-065657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017025065657/myo-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065657
- JSON: https://secwatch.observer/filing/0000950170-25-065657.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.